Plasma haemoxygenase-1 in coronary artery diseaseA comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor
30 November 2009
Accepted after major revision:27 June 2010
24 November 2017 (online)
It was the aim of this study to determine plasma haemoxygenase-1 (HO-1) across the spectrum of health, angina but normal coronary arteries (NCA), stable coronary artery disease (CAD), and acute coronary syndromes (ACS), and relationships with angiogenin, matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1, and vascular endothelial growth factor. Plasma markers were measured (ELISA) in peripheral venous citrated plasma from 50 healthy subjects, 30 with NCA, 70 with stable CAD and 24 with an ACS, and from patient’s aortic root, coronary ostium, coronary sinus and femoral artery. Human umbilical vein endothelial cells (HUVECs) were cultured with or without tumour necrosis factor (TNF), and platelets were probed. HO-1 was raised in stable CAD (p<0.05) and increased further in ACS (p<0.01) compared to healthy controls and NCA. HO-1 correlated only with MMP-9, and then only in the healthy controls. There were no major differences from cardiac or peripheral sites. HO-1 was present in HUVECs and 24-hour HUVEC supernatants but release was abolished by TNF. Platelets had no HO-1. In conclusion, HO-1 is raised in stable CAD and ACS and may arise from the endothelium but not the platelet. This may have implications for our understanding of the pathophysiology of CAD and its acute presentation as ACS.
- 1 Tousoulis D, Davies G, Stefanadis C. et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993-997.
- 2 Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006; 47 (Suppl. 08) C7-12.
- 3 Barguer AC, Beeuwes 3rd R, Lainey LL. et al. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-177.
- 4 Tayebjee MH, Lip GY, Blann AD. et al. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and –9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and –2. Thromb Res 2005; 115: 205-210.
- 5 Khurana R, Simons M, Martin JF. et al. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005; 112: 1813-1824.
- 6 Celletti FL, Waugh JM, Amabile PG. et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 07: 425-429.
- 7 Moulton KS, Heller E, Konerding MA. et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E–deficient mice. Circulation 1999; 99: 1726-1732.
- 8 Heeschen C, Dimmeler S, Hamm CW. et al. CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators.. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003; 107: 524-530.
- 9 Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110: 2355-2360.
- 10 Kishimoto K, Liu S, Tsuji T. et al. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005; 24: 445-446.
- 11 Tello-Montoliu A, Marín F, Patel J. et al. Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J 2007; 28: 3006-3011.
- 12 Ponka P. Cell biology of heme. Am J Med Sci 1999; 318: 241-256.
- 13 Morita T. Hemeoxygenase and atherosclerosis. Arterscler Thromb Vasc Biol 2005; 25: 1786-1808.
- 14 Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79–127. Erratum in: Pharmacol Rev 2008; 60: 242.
- 15 Deramaudt BM, Braunstein S, Remy P. et al. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem 1998; 68: 121-127.
- 16 Jozkowicz A, Huk I. Nigisch et al. Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid Redox Signal 2003; 05: 155-162.
- 17 Bussolati B, Ahmed A, Pemberton H. et al. Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration. Blood 2004; 103: 761-766.
- 18 Fernandez M, Bonkovsky HL. Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane. Br J Pharmacol 2003; 139: 634-640.
- 19 Thygesen K, Alpert JS, White HD. on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal Definition of Myocardial Infarction. Circulation 2007; 116: 2634-2653.
- 20 Bernardo A, Ball C, Nolasco L. et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra large von Willebrand factor multimers under flow. Blood 2004; 104: 100-106.
- 21 Altman DG. Practical statistics for Medical Research. Chapman and Hall; London: 1991. pp. 219-220.
- 22 Ishikawa K, Sugawara D, Wang XP. et al. Heme oxygenase-1 inhibits athero-sclerotic lesion formation in LDL-receptor knockout mice. Circ Rec 2001; 88: 506-512.
- 23 Idriss NK, Blann AD, Lip GY. Hemoxygenase-1 in cardiovascular disease. J Am Coll Cardiol 2008; 52: 971-978.
- 24 Morsi WG, Shaker OG, Ismail EF. et al. HO-1 and VEGF gene expression in human arteries with advanced atherosclerosis. Clin Biochem 2006; 39: 1057-1062.
- 25 Jazwa A, Loboda A, Golda S. et al. Effect of heme and heme oxygenase-1 on vascular endothelial growth factor synthesis and angiogenic potency of human keratinocytes. Free Radic Biol Med 2006; 40: 1250-1263.
- 26 Lüblinghoff N, Winkler K, Winkelmann BR. et al. Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study). BMC Med Genet 2009; 10: 36-42.
- 27 Yachie A, Niida Y, Wada T. et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 1999; 103: 129-135.
- 28 Kirino Y, Takeno M, Murakami S. et al. Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis Rheum 2007; 56: 464-475.
- 29 Kinderlerer AR, Pombo Gregoire I, Hamdulay SS. et al. Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin. Blood 2009; 113: 1598-1607.
- 30 Chen SM, Li YG, Wang DM. Study on changes of heme oxygenase-1 expression in patients with coronary heart disease. Clin Cardiol 2005; 28: 197-201.
- 31 Chen SM, Li YG, Wang DM. et al. Expression of heme oxygenase-1, hypoxia inducible factor-1 alpha, and ubiquitin in peripheral inflammatory cells from patients with coronary heart disease. Clin Chem Lab Med 2009; 47: 327-333.
- 32 Brydun A, Watari Y, Yamamoto Y. et al. Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis. Hypertens Res 2007; 30: 341-348.
- 33 Devey L, Ferenbach D, Mohr E. et al. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol Ther 2009; 17: 65-72.
- 34 Stark M, Zubareb J, Jacovovitz R. et al. HO-1 and VEGF gene expressions are time dependent during exposure to welding fumes. Cytokine 2009; 46: 290-295.
- 35 Cheng C, Noordeloos AM, Jeney V. et al. Heme oxygenase 1 determines athero-sclerotic lesion progression into a vulnerable plaque. Circulation 2009; 119: 3017-3027.
- 36 Bussolati B, Mason JC. Dual role of VEGF-induced heme-oxygenase-1 in angio-genesis. Antioxid Redox Signal 2006; 08: 1153-1163.
- 37 Dulak J, Deshane J, Jozkowicz A. et al. Heme oxygenase-1 and carbon monoxide in vascular pathobiology. Focus on angiogenesis. Circulation 2008; 117: 231-241.
- 38 Ali F, Hamdulay SS, Kinderlerer AR. et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 2007; 05: 2537-2546.
- 39 Loboda A, Jazwa A, Jozkowicz A. et al. Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect hemeoxygenase-1 in human microvascular endothelials cells. Atherosclerosis 2006; 187: 26-30.
- 40 Grosser N, Erdmann K, Hemmerle A. et al. Rosuvastatin upregulates the antioxidant defence protein Heme oxygenase-1. Biochem Biophys Res Commun 2004; 325: 871-876.
- 41 Lee Ts, Chang CC, Zhu Y. et al. Simvastastin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004; 110: 1296-1302.
- 42 Kronke G, Kadl A, Ikonomu E. et al. Expression of heme oxygenase-1 in human vascular endothelial cells is regulated by peroxisome proliferator-activated receptors. Arterioscl Thromb Vasc Biol 2007; 27: 1276-1282.
- 43 Grochot-Przeczek A, Dulak J, Jozkowicz A. Haemoxygenase-1 in neovascularisation: A diabetic perspective. Thromb Haemost 2010; 104: 424-431.